Professor of Medicine, Vanderbilt University
Oncology
Dr. Kenneth R. Hande, MD
|
|
Give Review
Kenneth Hande is an expert in the field of Oncology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He received awards:"Fellow (FASCO)". Kenneth Hande is also a published doctor. He has 98 publication published. The most recent publication is: Etoposide: four decades of development of a topoisomerase II inhibitor.
Publications
- Combination of vinblastine and bleomycin in metastatic renal cell carcinoma.
- Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
- Effect of hydration on plasma-methotrexate levels.
- Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
- Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.
- Current perspectives in small cell lung cancer.
- Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer.
- Drug monitoring in cancer therapy.
- The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits.
- In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
- Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
- Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats.
- Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer.
- Pharmacologic-based dosing of carboplatin: a better method.
- Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia.
- Metabolism and excretion of etoposide in isolated, perfused rat liver models.
- Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
- Protection from cisplatin nephrotoxicity by A68828, an atrial natriuretic peptide.
- The role of the renin-angiotensin system in cisplatin nephrotoxicity.
- Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.
- Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
- Chemotherapy and radiation therapy for non-small cell lung carcinoma.
- Etoposide pharmacology.
- Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide.
- Treatment of intraocular lymphoma with high-dose Ara-C.
- Chemotherapy prior to local therapy in advanced squamous cell carcinoma of the head and neck: Preliminary assessment of an intensive drug regimen.
- Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit.
- High-dose methotrexate in combination chemotherapy for small cell lung cancer.
- Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids.
- Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis.
- Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung.
- The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.
- The effect of cimetidine on cyclophosphamide metabolism in rabbits.
- The feasibility of adjuvant surgery in limited-stage small cell carcinoma: a prospective evaluation.
- Favorable prognosis of brain metastases in small cell lung cancer.
- Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt...
- High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung.
- Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
- Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
- Disseminated Merkel cell tumor. Treatment with systemic chemotherapy.
- Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung.
- Acute nonlymphocytic leukemia after treatment of small cell lung cancer.
- High-dose pilot studies in extensive-stage small-cell lung cancer.
- A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Ce...
- High-dose methotrexate with citrovorum factor rescue in non-small-cell lung cancer.
- High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
- Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical a...
- Clinical applications of anticancer drugs targeted to topoisomerase II.
- Current status of etoposide in the management of small cell lung cancer.
- Etoposide kinetics in patients with obstructive jaundice.
- Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
- Somatostatin analogue phase I trials in neuroendocrine neoplasms.
- Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome.
- Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
- High-dose etoposide (VP-16) in small-cell lung cancer.
- Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
- Chronic oral etoposide in the treatment of lung cancer.
- Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
- Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
- The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer.
- High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.
- Combination chemotherapy with oral etoposide.
- Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
- Bioavailability of low-dose oral etoposide.
- Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
- Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer.
- Combined small-cell and non-small-cell lung cancer.
- Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
- Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
- Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer.
- Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
- Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46.
- Topoisomerase II inhibitors.
- A randomized Phase II trial in patients with carcinoma of an unknown primary site.
- Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
- Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
- Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
- Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
- Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
- A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
- Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
- Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial.
- A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer.
- Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens.
- Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
- Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
- Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
- Bone cancer.
- Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
- A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
- Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results ...
- Developing an in-training examination for fellows: the experience of the American Society of Clinical Oncology.
- The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
- Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
- A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affil...
- New drugs on the horizon: matrix metalloproteinase inhibitors.
- Etoposide: four decades of development of a topoisomerase II inhibitor.
Schools
Johns Hopkins Univ Sch Of Med
Barnes Jewish Hospital
National Cancer Institute
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow (FASCO)
Education
-
Washington University - Barnes-Jewish Hospital -
Johns Hopkins University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Helpful Reviews
Similar Doctors
|
Dr. William C. Penley, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ingrid Mayer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jordan D. Berlin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Howard A. Burris III, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Igor Puzanov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven N. Wolff, MD |
|
|
Dr. John D. Hainsworth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Doukas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alicia K. Morgans, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laquisa C. Hill, MD |
|
|
Dr. Valerie M. Jansen, MD |
|
|
Dr. Charles E. McKay, MD |